This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Uriel Halbreich, MD
Department of Psychiatry Erie County Medical Center, K Annex SUNY at Buffalo 4624 Griden St Buffalo, NY 14215

Arch Gen Psychiatry. 1995;52(7):606.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

An association between premenstrual dysphoric disorder (PDD) (or premenstrual syndrome [PMS]) and major depressive disorder (MDD) has been demonstrated by several groups.¹ Various biological factors that have been shown to be abnormal in patients with MDD were also reported to be abnormal in women with dysphoric PMS,^2,3 and several antidepressants have been shown to be effective for the treatment of PMS. However, women with PMS also have been reported to be more sensitive to develop anxiety symptoms in response to lactate infusions⁴ and carbon dioxide inhalation⁵—stimuli that were reported to distinguish patients with panic disorders. Now, increased sensitivity of women with PDD to the panicogenic compound cholecystokinin-tetrapeptide is reported by Le Melledo et al in their letter above.

Levels of some of the variables that are abnormal in patients with MDD fluctuate along the menstrual cycles,⁶ but it is of importance that some variables . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?